X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (330) 330
index medicus (311) 311
oncology (278) 278
everolimus (273) 273
rad001 (245) 245
sirolimus - analogs & derivatives (204) 204
mammalian target (197) 197
cancer (157) 157
rad001 everolimus (150) 150
female (142) 142
mtor (142) 142
rapamycin (137) 137
cell line, tumor (110) 110
animals (108) 108
male (108) 108
sirolimus - pharmacology (106) 106
tor serine-threonine kinases - antagonists & inhibitors (104) 104
middle aged (89) 89
antineoplastic agents - therapeutic use (85) 85
sirolimus - administration & dosage (84) 84
aged (82) 82
sirolimus - therapeutic use (81) 81
apoptosis (73) 73
adult (71) 71
care and treatment (71) 71
tor serine-threonine kinases - metabolism (71) 71
tumors (71) 71
mice (70) 70
cell proliferation - drug effects (69) 69
tor serine-threonine kinases (66) 66
pathway (63) 63
pharmacology & pharmacy (62) 62
mtor inhibitor (61) 61
activation (57) 57
chemotherapy (57) 57
research (56) 56
therapy (56) 56
antineoplastic agents - pharmacology (55) 55
expression (52) 52
phase-ii (52) 52
treatment outcome (52) 52
medicine & public health (51) 51
growth (50) 50
signal transduction - drug effects (49) 49
phosphorylation (48) 48
signal transduction (48) 48
akt (47) 47
analysis (46) 46
antineoplastic combined chemotherapy protocols - therapeutic use (46) 46
kinases (46) 46
sirolimus - adverse effects (46) 46
angiogenesis inhibitors (45) 45
hematology (45) 45
proteins (45) 45
apoptosis - drug effects (44) 44
dose-response relationship, drug (44) 44
protein kinase inhibitors - therapeutic use (44) 44
metastasis (40) 40
proto-oncogene proteins c-akt - metabolism (40) 40
cancer therapies (39) 39
in-vitro (39) 39
neoplasms - drug therapy (38) 38
cancer research (36) 36
drug synergism (36) 36
efficacy (36) 36
hematology, oncology and palliative medicine (36) 36
phase-ii trial (36) 36
neuroendocrine tumors (35) 35
drug therapy (34) 34
induced apoptosis (34) 34
xenograft model antitumor assays (34) 34
autophagy (33) 33
neuroendocrine tumors - drug therapy (33) 33
survival (33) 33
article (32) 32
cell growth (32) 32
renal-cell carcinoma (32) 32
breast cancer (31) 31
breast-cancer (31) 31
health aspects (31) 31
immunosuppressive agents - therapeutic use (31) 31
mtor inhibitors (31) 31
antineoplastic agents - adverse effects (29) 29
cell survival - drug effects (29) 29
clinical trials (29) 29
inhibition (29) 29
aged, 80 and over (28) 28
antineoplastic combined chemotherapy protocols - pharmacology (28) 28
cell cycle (28) 28
studies (28) 28
cell biology (27) 27
endothelial growth-factor (27) 27
everolimus rad001 (27) 27
immunosuppressive agents - pharmacology (27) 27
protein kinase inhibitors - pharmacology (27) 27
carcinoma, renal cell - drug therapy (26) 26
cell cycle - drug effects (26) 26
disease-free survival (26) 26
endocrinology & metabolism (26) 26
kidney neoplasms - drug therapy (26) 26
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 09/2009, Volume 15, Issue 17, pp. 5404 - 5413
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 04/2009, Volume 8, Issue 4, pp. 742 - 753
Journal Article
Proceedings of the National Academy of Sciences, ISSN 0027-8424, 09/2008, Volume 105, Issue 36, pp. 13544 - 13549
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates cell growth via mTOR complex 1 (mTORC1), whose activation has been... 
Rapamycin | Colon cancer | Adenoma | RAD001 | Mammalian target of rapamycin | Biological Sciences | mammalian target of rapamycin | adenoma | colon cancer | rapamycin
Journal Article
Recent Results in Cancer Research, ISSN 0080-0015, 2018, Volume 211, pp. 101 - 123
Journal Article
Journals of Gerontology - Series A Biological Sciences and Medical Sciences, ISSN 1079-5006, 06/2018, Volume 73, Issue 7, pp. 845 - 852
Rapalogs, inhibitors of mTORC1 (mammalian target of rapamycin complex 1), increase life span and delay age-related phenotypes in many species. However, the... 
Aging | Rapamycin | RAD001 | Myc | Kidney | EXTENDS LIFE-SPAN | LABORATORY RAT | STRATEGIES | GERIATRICS & GERONTOLOGY | DISEASE | GERONTOLOGY | CHRONIC PROGRESSIVE NEPHROPATHY | MICE | Biological Sciences | Editor's Choice | The Journal of Gerontology
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2630 - 2637
Purpose Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism... 
INHIBITOR RAD001 EVEROLIMUS | MAMMALIAN TARGET | ADVANCED SOLID TUMORS | ONCOLOGY | TAMOXIFEN | DOUBLE-BLIND | ENDOCRINE THERAPY | AKT | POSTMENOPAUSAL WOMEN | PROGNOSTIC VALUE | MTOR | Cyclin D1 - metabolism | Palpation | Triazoles - administration & dosage | Phosphorylation | Receptors, Estrogen - metabolism | Ribosomal Protein S6 Kinases - metabolism | United States | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Nitriles - administration & dosage | Time Factors | Aged, 80 and over | Biomarkers, Tumor - metabolism | Postmenopause | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Everolimus | Aromatase Inhibitors - administration & dosage | Sirolimus - analogs & derivatives | Double-Blind Method | Europe | Treatment Outcome | Breast Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Gene Expression Regulation, Enzymologic | Phosphatidylinositol 3-Kinases - genetics | Sirolimus - administration & dosage | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Biopsy | Breast Neoplasms - pathology | Aged | Cell Proliferation - drug effects | Mutation | Index Medicus
Journal Article